Overview

Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions

Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well vandetanib works in preventing head and neck cancer in patients with precancerous head and neck lesions. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of vandetanib may keep cancer from forming in patients with premalignant lesions
Phase:
Phase 2
Details
Lead Sponsor:
University of Chicago
Collaborator:
National Cancer Institute (NCI)